> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/addendum-dosing-th1-th2-and-recalibration.md). # Addendum — Dosing, Th1/Th2, and Recalibration This addendum restores the full practical distinction from the source notes. A **transient high-exposure ROS pulse** is not the same thing as **continuous oral mega-dosing**. ### What the Th1/Th2 dose-dependent finding actually says The main concern is not simple toxicity. It is that **chronic high melatonin exposure may blunt Th1 signalling**. That means lower **IFN-γ** and **IL-12-linked priming** at the point where anti-tumour immunity needs them most. The key study here is **Szczepanik et al. 2007**. In a Th1-dependent immune model, melatonin suppressed **IFN-γ** and **IL-12** production in lymph node cells. The broader point is dose-dependent. Lower exposure can support Th1 activity. Higher exposure can shift toward **Th2** or broader immunosuppressive signalling. That pattern is consistent with later review and dendritic-cell literature as well. * **Carrillo-Vico et al.** describe melatonin as a dose-sensitive, double-edged inflammatory regulator. * **Huang et al. 2024** show melatonin can suppress **Th1** and **Th17** responses through dendritic-cell **NF-κB** inhibition. ### Where this matters most in the cancer-immunity cycle The strongest leverage point is **Step 3 of the cancer-immunity cycle**. That is the **priming and activation** phase in the lymph nodes. This is where dendritic cells present tumour antigens and need Th1-skewed help to set up the rest of the response. That includes: * efficient **CD8 cross-priming** * stronger **memory formation** * more tumouricidal **macrophage polarisation** If Th1 tone is weak here, later steps can stall. That includes trafficking, infiltration, recognition, and tumour killing. So if continuous high-dose melatonin chronically blunts **IFN-γ** and **IL-12** at this step, it can weaken the priming phase before later therapies even get a fair chance to work. ### Why the RET mechanism does not justify continuous oral mega-dosing This is the main practical misunderstanding. The two key mechanistic studies do not model indefinite oral human use. * **Benaiges et al.** used **40 mg/kg intraperitoneal melatonin** in mice * **Florido et al.** used direct **0.5 to 1 mM exposure** in cancer cells over a short time window Both support a **brief ROS event**. The cell-line work points to a burst that peaks within roughly **1 to 3 hours**. That burst does not imply that repeating a large oral dose every day creates a stronger and stronger RET effect. Tumour cells do not appear to experience an endlessly compounding RET stimulus from chronic oral intake. What rises more reliably with continuous daily use is the ongoing melatonin load. That shifts the question away from a short pro-oxidant pulse and toward **chronic signalling**, **immune modulation**, **CYP1A2 effects**, and endocrine load. {% hint style="warning" %} A supervised short-term high-exposure pulse and unsupervised chronic oral mega-dosing should not be treated as equivalent strategies. {% endhint %} ### The evidence-supported adjunct window The clinical and preclinical literature is most consistent in the **moderate adjunct range**. For most readers not pursuing a defined supervised pulse strategy, the main evidence-supported range remains: * **1 to 20 mg nightly** as the lower physiological to low-pharmacological range * **20 to 40 mg nightly** as the main moderate adjunct range used in human oncology discussions The main human oral dosing data here comes from the **Lissoni trials** and the **Mills meta-analysis**. Those reports used **20 to 40 mg oral melatonin** in cancer patients and measured **clinical outcomes**, not just laboratory markers. That is the zone most aligned with: * circadian support * Th1-skewed immune support * IL-2 and IFN-γ support * checkpoint-related adjunct logic By contrast, **continuous daily hundreds-of-mg oral use** sits in a weaker evidence zone and carries more risk of working against the immune goal. ### Route, bioavailability, and the uncertain middle zone Not all dose claims in the melatonin discussion come from the same type of study. That matters because **route changes exposure**. The **Th1-support and clinical-outcome claims** come from real human oral trials. Cancer patients in the Lissoni work took **20 to 40 mg by mouth at night**. Those are swallowed oral doses in actual patients. No route conversion is needed there. The **RET and some mitochondrial claims** come from mice given injections or from cells exposed directly in culture. That is a different exposure model. When melatonin is injected intraperitoneally in mice, most of the dose reaches systemic circulation much more directly than a swallowed powder dose in humans. Using standard scaling, the **40 mg/kg mouse intraperitoneal dose** maps to roughly **225 mg reaching the bloodstream** in a human-sized adult. That does **not** mean swallowing 225 mg plain powder reproduces the model. With rough oral absorption assumptions: * around **2 to 2.3 g plain powder** may be needed to deliver about **225 mg systemically** * around **600 mg swallowed** in a high-efficiency liposomal or alcohol-solubilised form may reach a similar systemic exposure That creates an important middle zone. A practical example is **400 mg plain powder orally**. That may deliver only about **40 mg systemically**. So it may be: * **too low** to clearly reproduce the mouse-equivalent RET exposure * **too high** to still look like classic human adjunct dosing That is the uncertain middle zone. The immune downside may rise before the RET-style upside is even reached. ### Recalibration framework If someone has been taking continuous high doses, the most practical next step is not panic. It is reassessment. These effects are pharmacological. They are not best understood as a permanently fixed immune fate. Useful next steps include: * review the reason for the current dose * separate **RET-pulse logic** from **nightly adjunct logic** * revisit timing, formulation, and interaction questions * discuss the protocol with the oncology team when immunotherapy or multiple medicines are involved If there was no defined supervised RET-pulse rationale, the better-supported default is usually to step back toward the **10 to 40 mg nightly evening range**. That is the range with the clearest human adjunct signal for circadian support, Th1 support, and checkpoint-relevant immune framing. ### Bottom line The better-supported human melatonin use case remains **moderate evening adjunct dosing**. Continuous daily high-dose oral use is a different strategy. It has weaker evidence, greater route uncertainty, and more risk of working against the immune goal. ### Related pages * [Melatonin in Oncology - Study Notes](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes.md) — the hub page that ties together the mitochondria, dosing, immune, phase-separation, and fibrosis sections * [Moderate-Dose Immune Effects and Timing](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/moderate-dose-immune-effects-and-timing.md) — the human oral adjunct literature, Th1 logic, and timing framework * [Dosing, Bioavailability, and Human Scaling](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/dosing-bioavailability-and-human-scaling.md) — how mouse and cell data translate into estimated human exposure, route limits, and bioavailability caveats * [High-Dose Mitochondria, RET, and ROS](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/high-dose-mitochondria-ret-and-ros.md) — the mechanistic RET, ROS, uncoupling, and apoptosis sequence behind the high-dose claim * [DIY Liposomal Melatonin](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/diy-liposomal-melatonin.md) — formulation notes, storage, costing, and practical liposomal-delivery context ### Key references * Szczepanik et al. 2007 — melatonin and Th1-dependent responses\ * Carrillo-Vico et al. — melatonin and inflammation\ * Huang et al. 2024 — dendritic-cell NF-κB and Th1/Th17 suppression\ * Benaiges et al. — RET-linked tumour-control model in mice\ * Florido et al. 2022 — ROS burst and reverse electron transport mechanism\ * Lissoni clinical oncology paper\ * Mills et al. 2005 — meta-analysis of melatonin trials in cancer patients\ * Chen and Mellman 2013 — cancer-immunity cycle\ --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/addendum-dosing-th1-th2-and-recalibration.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.